Cancer -
page-template-default,page,page-id-205,bridge-core-2.4.3,qode-page-transition-enabled,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-25.7,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-6.6.0,vc_responsive


Immunotherapy using therapeutic cancer vaccines has the potential to address several unmet medical needs.

Vaccibody therapeutic cancer vaccines may offer well tolerated treatment options for a broad range of cancer indications and treatment settings.


One of Vaccibody’s strategic pillars is cancer vaccines and the Company is currently running two studies:

  • A phase I/IIa study testing its personalized neoantigen cancer vaccine, VB10.NEO, in patients with locally advanced or metastatic cancer.
  • A phase II study testing its HPV16 directed cancer vaccine in patients with advanced, non-resectable cervical cancer.